Meeting
2016 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
Authors
Jose Baselga
Memorial Sloan Kettering Cancer Center, New York, NY
Jose Baselga , Javier Cortes , Michele De Laurentiis , Veronique Dieras , Nadia Harbeck , Jerry Y. Hsu , Vivian Ng , Frauke Schimmoller , Timothy R. Wilson , Young-Hyuck Im , William Jacot , Ian E. Krop , Sunil Verma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02340221
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS617)
DOI
10.1200/JCO.2016.34.15_suppl.TPS617
Abstract #
TPS617
Poster Bd #
103a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
First Author: Jose Baselga
Poster
2015 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.
First Author: Jose Baselga
Poster
2016 ASCO Annual Meeting
A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).
First Author: Maura N. Dickler
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer